Table 4.

Relative HRs (95% CI) of mortality risks compared with non-diabetes participants with UA 5–7 mg/dL among participants without diabetes and with diabetes.

Risks	Non-DM				DM
	<5 (mg/dL) N = 11,545	5–7 (mg/dL) N = 11,895	7–9 (mg/dL) N = 3030	≥9 (mg/dL) N = 250	<5 (mg/dL) N = 973	5–7 (mg/dL) N = 1141	7–9 (mg/dL) N = 345	≥9 (mg/dL) N = 47
All-cause mortality (N = 2069)
un-weighted	1.04 (0.9–1.19)	1.0 (reference)	1.24 (1.05–1.47) *	2.37 (1.58–3.55) *	1.77 (1.44–2.18) *	1.43 (1.17–1.76) *	2.55 (1.94–3.34) *	2.25 (1.06–4.77) *
weighted a	1.06 (0.9–1.26)	1.0 (reference)	1.40 (1.12–1.75) *	2.35 (1.39–3.96) *	2.01 (1.55–2.62) *	1.30 (0.95–1.76)	2.87 (2.14–3.85) *	2.79 (1.28–6.08) *
CVD mortality (N = 495)
un-weighted	1.03 (0.77–1.39)	1.0 (reference)	1.39 (0.98–1.98)	3.06 (1.42–6.62) *	1.71 (1.08–2.69) *	2.12 (1.46–3.09) *	3.25 (1.89-5.61) *	3.38 (0.82–13.87)
weighted a	1.23 (0.86–1.76)	1.0 (reference)	1.74 (1.18–2.57) *	5.07 (1.71–5.04) *	2.21 (1.14–4.28) *	2.25 (1.25–4.06) *	4.99 (2.48–10.03) *	1.66 (0.42–6.60)
Cancer death (N = 520)
un-weighted	1.04 (0.81–1.34)	1.0 (reference)	1.10 (0.80–1.50)	2.42 (1.18–4.94) *	1.58 (1.07–2.33) *	0.82 (0.52–1.30)	1.28 (0.69–2.39)	1.84 (0.45–7.47)
weighted a	1.07 (0.77–1.49)	1.0 (reference)	1.23 (0.88-1.71)	1.43 (0.64–3.19)	1.45 (0.77–2.72)	0.78 (0.45–1.35)	1.54 (0.75–3.17)	3.30 (0.76–14.37)
CVD or Cancer death (N = 1015)
un-weighted	1.04 (0.86–1.26)	1.0 (reference)	1.22 (0.96–1.54)	2.67 (1.58–4.51) *	1.62 (1.21–2.18) *	1.35 (1.02–1.80) *	2.01 (1.34–3.02) *	2.40 (0.89–6.50)
weighted a	1.13 (0.86–1.47)	1.0 (reference)	1.40 (1.06–1.84) *	2.58 (1.21–5.54) *	1.69 (1.14–2.51) *	1.28 (0.89–1.84)	2.67 (1.68–4.26) *	2.81 (0.84–9.39)

^a Data are weighted estimates. Adjusted for BMI, sex, age, race, HDL-Cholesterol, current smoking status, SBP and creatinine. * p < 0.05.